Searchable abstracts of presentations at key conferences in endocrinology

ea0022p140 | Cardiovascular endocrinology and lipid metabolism | ECE2010

Atrial natriuretic peptide (ANP) attenuates lipid peroxidation in anesthetized atherosclerotic male rabbits by reduction of renin-angotensin-aldosterone system (RAAS) activity

Kallaras Konstantinos , Karamouzis Michael , Stergiou-Michailidou Vassiliki , Zaraboukas Thomas

Reactive oxygen species (ROS) are involved in the pathogenesis of atherosclerosis. Atrial natriuretic peptide (ANP) reduces thioredoxin in heart failure patients, whereas adrenomedullin, acting as an antioxidant, protects rat cardiomyocytes from infarction and mouse vascular smooth muscle cells from angiotensin II (AII) oxidative effect. Besides AII, aldosterone (Aldo) is also an activator of ROS. Aim of the study was the investigation of the eventual antioxidant effect of ANP...

ea0022p289 | Diabetes | ECE2010

Association of diabetes mellitus with thalassaemia and sickle cell disease

Thisiadou Katerina , Karamouzis Ioannis , Arampatzi Stella , Tomos Kostantinos , Michailidou Despoina

Background: The majority of complications in transfusion dependent thallasemic and with sickle cell anemia patients are due to iron overload. This is responsible for the beginning of haemosiderosis, clinical symptoms and dysfunction of important systems, specially after the 2nd decade of life. The increase of the iron accumulation is caused by hemolysis, high iron absorbance and mainly by transfusion treatment. The appearance of diabetes mellitus depends on the significance an...

ea0077oc3.4 | Metabolism, Obesity and Diabetes | SFEBES2021

Hepatic choline deficiency underpins amelioration of visceral obesity and diabetes in ectonucleotide pyrophosphatase (Enpp)-6–/– mice

Wang Rongling , Schraut Katharina , Carter Roderick , Kentistou Katherine , Wilson James , Michailidou Zoi , Webster Scott , Morton Nicholas

The global prevalence of obesity continues to rise, creating a growing need for new effective medicines. Selective targeting of visceral obesity (fat around the internal organs) would be particularly advantageous because it carries a greater risk for cardiometabolic diseases. The ectonucleotide pyrophosphatase (ENPP) enzyme family participates in several pathological conditions including diabetes (ENPP1, and ENPP2, also known as autotaxin) and vascular dysfunction (ENPP3-4). O...

ea0077lb12 | Late Breaking | SFEBES2021

Hypoxia re-programmes adipocyte metabolism to drive cancer cell proliferation

Aird Rhona , Wills Jimi , Roby Katherine , Stimson Roland , Finch Andy , Michailidou Zoi

Obesity increases the risk of certain cancers, especially tumours that reside close to adipose tissue (e.g. breast cancers and ovarian metastasis to omentum). Adipose tissue in obesity and tumour micro-environmentsshare a common pathogenic feature, oxygen deprivation (hypoxia, Hx). Here we hypothesised that this hypoxic microenvironment causes changes in key metabolic pathways in adipocytes leading to increased cancer cell growth. To test this, human or mouse breast (BC) and o...

ea0038p243 | Obesity, diabetes, metabolism and cardiovascular | SFEBES2015

Markers of adipose tissue hypoxia are elevated in subcutaneous adipose tissue of morbidly obese patients with hypoventilation syndrome and obstructive sleep apnoea syndrome but not in the moderately obese

Todorčević Marijana , Austen Luke , Manuel Ari , Michailidou Zoi , Stradling John , Karpe Fredrik

Adipose tissue (AT) dysfunction is thought to be a central component in the pathophysiology of obesity-associated metabolic disease. Low AT oxygenation (hypoxia) is suggested to be a driver of this dysfunction, yet studies in humans have resulted in conflicting data. Therefore, we aimed to investigate if markers of AT hypoxia were present in the subcutaneous AT of morbidly obese individuals who had hypoxia from obesity hypoventilation syndrome (OHS), with or without obstructiv...

ea0022p80 | Bone/Calcium | ECE2010

Secondary hypoparathyroidism in thalassaemia and sickle cell anaemia

Thisiadou Katerina , Karamouzis Ioannis , Arampatzi Stella , Chalvatzi Kiriaki , Hasapopoulou Eleni , Michailidou Despoina

Background: The diagnosis of hypoparathyroidism, a clinical situation characterised by reduced production of parathyroid hormone despite the low calcium level, depends on patient’s anamnesis, clinical aspect and the biochemical parameters.Thalassaemia, an inherited autosomal recessive blood disease, caused by the reduced capacity of erythroblasts to synthesize one of the chains that build up hemoglobine. The combination of transfusion and chelation ...

ea0022p81 | Bone/Calcium | ECE2010

Abnormalities in calcium, phosphorus and parathyroid hormone in patients with end stage chronic kidney disease on hemodialysis

Thisiadou Katerina , Karamouzis Ioannis , Arampatzi Stella , Tsolakidou Alexandra , Sioulis Athanasios , Michailidou Despoina

Introduction: The decline of renal function is closely associated to increased parathyroid hormone secretion, resulting to secondary hyperparathyroidism because of: 1) hypocalcemia; 2) hyperphosphatemia; 3) reduced activity of calcitriol; 4) skeletal resistance to the calcemic action of parathyroid hormone (PTH) and 5) reduced secretion of the calcium-sensing receptor (CaSR) in the parathyroid glands.The retention of phosphorus is considered to take an i...

ea0011oc27 | Diabetes and metabolism | ECE2006

A selective increase in adipose 11β-HSD1 expression in corticosterone-treated Pomc null mice is associated with development of metabolic syndrome

Michailidou ZM , Coll APC , Morton NMM , Kenyon CJ , O’Rahilly S , Seckl JR , Chapman KE

Inactivating mutations of the POMC gene in humans and mice result in a complex phenotype of hyperphagia, obesity and glucocorticoid (GC) deficiency, but without many features of metabolic syndrome. We have previously shown that replacement of GC in Pomc−/− mice exacerbates their hyperphagia, increases fat mass and elevates plasma leptin and insulin. We have now examined key determinants of glucocorticoid action, including glucocorticoid receptor (...

ea0011p385 | Diabetes, metabolism and cardiovascular | ECE2006

Dietary regulation of peripheral glucocorticoid action: comparison of saturated and unsaturated fats

Man TY , Ramage L , Gokcel A , Michailidou Z , Kenyon CJ , Chapman K , Seckl JR , Morton NM

Obesity/Metabolic syndrome (insulin resistance, hypertension, cardiovascular disease) has reached epidemic levels in western societies. Aberrantly elevated glucocorticoid amplification by intracellular enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1) within adipose tissue might explain the striking similarities between idiopathic obesity/metabolic syndrome and Cushing’s syndrome, causes by plasma GC excess. A major contributor to obesity/metabol...

ea0031p315 | Steroids | SFEBES2013

11βHSD1 deficiency increases susceptibility to liver fibrosis by activating hepatic stellate cells

Zou Xiantong , Pellicoro Antonella , Aucott Rebecca , Ramachandran Prakash , Clarkson Michelle , Webster Scott P , Iredale John P , Walker Brian R , Michailidou Zoi

Background: Liver fibrosis in cirrhosis is characterized by accumulation of extracellular matrix from activated hepatic stellate cells (HSCs). Glucocorticoids (GCs) limit HSC activation in vitro. Local GC levels are regulated by 11β-hydroxysteroid dehydrogenase-1 (11βHSD1) which converts inactive GCs (11-dehydrocorticosterone) into active GCs (corticosterone). In this study we hypothesized that 11βHSD1 could potentially inhibit liver fibrosis.<p cla...